GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Annovis Bio Inc.
Annovis Bio is a biotech company developing drugs to treat neurodegenerative diseases such as Alzheimer's. Its stock price is highly volatile and driven by news from its clinical trials.
Share prices of companies in the market segment - Neuro
Annovis Bio is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. We've categorized it under "Neurology," and the chart below shows how investors assess the risks and prospects in this complex area of medicine.
Broad Market Index - GURU.Markets
Annovis Bio is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ANVS - Daily change in the company's share price Annovis Bio Inc.
For Annovis Bio, Inc., which develops drugs for neurodegenerative diseases, daily price change is a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to risk assessment.
Daily change in the price of a set of shares in a market segment - Neuro
Annovis Bio, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with ANVS, which focuses on neurodegenerative diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Annovis Bio is a biotech company developing drugs to treat neurodegenerative diseases. Its shares are known for their high volatility, driven by expectations and clinical trial results. This is a prime example of how a single story can create powerful market ripples.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Annovis Bio Inc.
Annovis Bio, Inc.'s year-over-year performance is a story about developing a drug for the treatment of neurodegenerative diseases. Its 12-month market cap depends entirely on clinical trial data for its lead candidate for Alzheimer's and Parkinson's diseases. Success could be a breakthrough, but the risks in this field are extremely high.
Annual dynamics of market capitalization of the market segment - Neuro
Annovis Bio, Inc. is a clinical-stage biotech company developing drugs for the treatment of neurodegenerative diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks involved.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Annovis is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor expectations for the success of its drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Annovis Bio Inc.
Annovis Bio is a clinical-stage biotech company targeting neurodegenerative diseases. Its monthly performance is entirely dependent on the results of its clinical trials. Data for its drug for Alzheimer's and Parkinson's diseases is subject to sharp fluctuations.
Monthly dynamics of market capitalization of the market segment - Neuro
Annovis Bio is a biotech company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's by restoring normal nerve cell function. The chart below reflects the mood in the neuroscience sector, where every success brings enormous hope.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Annovis Bio, Inc. is a clinical-stage biotech company developing drugs for the treatment of neurodegenerative diseases. Its stock is highly volatile, driven by clinical trial results. This is a classic biotech story, unrelated to the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Annovis Bio Inc.
Short-term fluctuations at Annovis Bio, a biopharmaceutical company developing drugs for neurodegenerative diseases, are extremely high. Any data, even preliminary, from clinical trials for Alzheimer's and Parkinson's diseases causes sharp fluctuations.
Weekly dynamics of market capitalization of the market segment - Neuro
Annovis Bio shares, like those of the entire neuroscience biotech sector, are driven by overall investor sentiment and news of breakthroughs. The success or failure of one major study can impact the entire industry. The chart shows how the company fares against this volatile backdrop.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Annovis Bio shares, like those of the entire neuroscience biotech sector, are driven by overall investor sentiment and news of breakthroughs. The success or failure of one major study can impact the entire industry. The chart shows how the company fares against this volatile backdrop.
Market capitalization of the company, segment and market as a whole
ANVS - Market capitalization of the company Annovis Bio Inc.
Annovis Bio's market capitalization is the financial valuation of a biotech company developing a drug to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. The chart reflects both the high hopes and skepticism of investors. Its highly volatile dynamics tell the story of how the market reacts to each piece of clinical trial data.
ANVS - Share of the company's market capitalization Annovis Bio Inc. within the market segment - Neuro
Annovis Bio is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. Its sector share reflects the market's confidence in its lead candidate. The chart below is a barometer of market confidence in its approach to treating these complex diseases.
Market capitalization of the market segment - Neuro
Annovis Bio is a biopharmaceutical company developing drugs for neurodegenerative diseases such as Alzheimer's and Parkinson's. The chart below shows the overall market capitalization of the entire sector. Its dynamics reflect the hopes for a breakthrough in this highly complex field of medicine.
Market capitalization of all companies included in a broad market index - GURU.Markets
Alzheimer's disease is the primary target for many biotechs visible on the chart. Annovis Bio is developing a drug that, according to its theory, can halt neurodegeneration in Alzheimer's and Parkinson's diseases. Its market cap represents an extremely risky bet on its scientific hypothesis.
Book value capitalization of the company, segment and market as a whole
ANVS - Book value capitalization of the company Annovis Bio Inc.
Annovis Bio's book value is capital used to fight neurodegeneration. Currently in the R&D stage, the company is using its financial assets to support clinical trials of its lead drug, which could help treat Alzheimer's and Parkinson's diseases by restoring intra-nerve cell transport.
ANVS - Share of the company's book capitalization Annovis Bio Inc. within the market segment - Neuro
Annovis Bio, a clinical-stage biopharmaceutical company, focuses on neurodegenerative diseases. Its stake in the sector consists of R&D laboratories. Its value lies in the potential of its lead drug for the treatment of Alzheimer's and Parkinson's diseases.
Market segment balance sheet capitalization - Neuro
Annovis Bio, Inc. is a clinical-stage biotechnology company, which accounts for its low capital intensity. Its core value lies in developing drugs for the treatment of neurodegenerative diseases. Compared to the pharmaceutical sector, its "light" balance sheet is typical of companies focused on R&D.
Book value of all companies included in the broad market index - GURU.Markets
Annovis Bio's assets are not new molecules, but rather the development of a drug that could potentially treat Alzheimer's and Parkinson's diseases by restoring disrupted neuronal transport. The company's balance sheet reflects the value of this breakthrough idea. The chart shows the capital invested in this fundamental approach to neurodegeneration.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Annovis Bio Inc.
Annovis Bio is a biopharmaceutical company developing treatments for neurodegenerative diseases such as Alzheimer's. Its market capitalization is highly volatile, reflecting investor hopes for a breakthrough in this highly complex field.
Market to book capitalization ratio in a market segment - Neuro
Annovis Bio is a biotech company developing drugs to treat neurodegenerative diseases such as Alzheimer's. Its valuation is highly speculative and dependent on clinical trial data. This chart reflects the enormous promise and risks associated with this field.
Market to book capitalization ratio for the market as a whole
Annovis Bio is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's. Its market capitalization is based on the potential of its scientific developments. The chart shows the enormous premium investors pay for research in one of the most complex areas of medicine.
Debts of the company, segment and market as a whole
ANVS - Company debts Annovis Bio Inc.
Annovis Bio is a biotech company developing drugs to treat neurodegenerative diseases such as Alzheimer's. Clinical trials in this area are extremely expensive and risky. This chart shows how the company raises capital to fund its ambitious research programs.
Market segment debts - Neuro
Annovis Bio is a clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart shows how the company funds its expensive and risky clinical trials, which are almost always financed through equity capital due to the uncertainty of outcomes.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Annovis Bio Inc.
Annovis Bio, a biopharmaceutical company focused on neurodegenerative diseases such as Alzheimer's and Parkinson's, shows its leverage. This is the "holy grail" of pharmaceuticals, but also the biggest "graveyard" for clinical trials. High debt carries enormous risks.
Market segment debt to market segment book capitalization - Neuro
Annovis Bio is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart compares the debt it raised for this ambitious research with the overall market capitalization of the neuroscience sector. It illustrates the financial side of tackling some of the most complex diseases.
Debt to book value of all companies in the market
Annovis Bio is a biopharmaceutical company focused on treating neurodegenerative diseases such as Alzheimer's and Parkinson's. Funding clinical trials is its primary focus. The chart shows how the company manages its capital. Its debt load, compared to the biotech sector, reflects the high risks and potential of its developments.
P/E of the company, segment and market as a whole
P/E - Annovis Bio Inc.
For Annovis Bio, a company developing drugs to treat neurodegenerative diseases, this chart is a story of great hope. Investors' estimates of its potential profit are very high due to the company's huge market. The dynamics are a direct reaction to clinical trial data, which can either boost or depress the stock.
P/E of the market segment - Neuro
This chart reflects the average valuation for the speculative biotech sector—the benchmark for Annovis Bio. Comparison with this benchmark clearly demonstrates how volatile investor expectations can be. The sharp fluctuations in valuation across the sector and for the company reflect the hopes and disappointments of clinical trial data.
P/E of the market as a whole
Annovis Bio is a biotech company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. Its approach is to target a common pathological process. This chart shows the market's risk appetite. It provides insight into how investors view this ambitious but highly risky scientific approach and how research data influences valuation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Annovis Bio Inc.
Annovis Bio is a clinical-stage biopharmaceutical company developing a drug to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart reflects high hopes and high risks. It shows the potential value analysts assign to the company if its ambitious clinical trials are successful.
%20P%2FE%20Annovis%20Bio%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Annovis-Bio-Inc.&v=1772513825699 "Chart of the company's future (projected) P/E Annovis Bio Inc.")
Future (projected) P/E of the market segment - Neuro
Annovis Bio is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart shows how its profitability expectations compare to the biotech sector. It reflects investor confidence in its scientific approach aimed at restoring axonal transport.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772513825713 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Annovis Bio is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's. This chart shows the company's overall risk appetite. ANVS's success depends solely on clinical trial results. This is a high-risk position, unrelated to economics.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513825716 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Annovis Bio Inc.
Annovis Bio is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's by restoring normal nerve cell function. This chart shows the financial trajectory based on this innovative approach.
Profit of companies in the market segment - Neuro
Annovis Bio is a clinical-stage biopharmaceutical company developing a treatment for neurodegenerative diseases such as Alzheimer's and Parkinson's by improving axonal transport in the brain. This chart illustrates the total return in the neuroscience sector, reflecting the enormous risks and potential rewards of drug discovery for these devastating diseases.
Overall market profit
Annovis Bio is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's. Its prospects depend entirely on success in clinical trials. The business is not susceptible to economic cycles, but it requires significant investment, which is easier to attract in a growing market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Annovis Bio Inc.
Annovis Bio is a biotech company developing a drug to treat neurodegenerative diseases such as Alzheimer's and Parkinson's by enhancing brain signaling. This graph reflects the extremely high risks and potentially enormous rewards if its clinical trials are successful.
%20profit%20of%20the%20company%20Annovis%20Bio%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Annovis-Bio-Inc.&v=1772513825790 "Graph of future (projected) profit of the company Annovis Bio Inc.")
Future (predicted) profit of companies in the market segment - Neuro
Annovis Bio is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart shows forecasts for the biotech sector. Annovis's future profitability depends on the success of its unique approach aimed at restoring normal signaling in the brain, which can halt disease progression.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772513825809 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Annovis Bio develops drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. Funding for such breakthrough, yet risky, research depends on investor risk appetite. This graph, which displays earnings expectations, serves as an indicator of the stock market and investor appetite for long-term biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513825816 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Annovis Bio Inc.
Annovis Bio is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart shows that the company's valuation is based on expectations, reflecting its enormous potential if its clinical trials are successful.
P/S market segment - Neuro
Annovis Bio is a clinical-stage biopharmaceutical company developing a treatment for neurodegenerative diseases such as Alzheimer's and Parkinson's by improving axonal transport. This chart reflects the average biotech valuation, helping to understand how investors view the potential of this new approach to treating complex CNS diseases.
P/S of the market as a whole
Annovis Bio is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This revenue valuation indicator highlights that investors are not evaluating current sales, but rather the hope for a breakthrough in one of the most complex and in-demand areas of medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Annovis Bio Inc.
Annovis Bio is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart reflects investors' faith in its unique approach, which targets several neurotoxic proteins. The valuation is based on the enormous potential revenues if clinical trials are successful.
%20P%2FS%20Annovis%20Bio%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Annovis-Bio-Inc.&v=1772513825904 "The graph of the company's future (projected) P/S Annovis Bio Inc.")
Future (projected) P/S of the market segment - Neuro
Annovis Bio is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart compares the company's future revenue expectations with its industry. It reflects investor confidence in its scientific approach and the potential of its developments.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772513825919 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Annovis Bio is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart reflects confidence in future growth, as Annovis Bio is working to solve one of medicine's most complex problems. The success of its therapy could bring hope to millions.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513825951 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Annovis Bio Inc.
Annovis Bio is a clinical-stage biopharmaceutical company developing drugs for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. Currently, the company has no commercial sales revenue. Any revenue shown in the chart is related to research funding.
Sales of companies in the market segment - Neuro
Annovis Bio is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart reflects the enormous investment and hopes associated with finding cures for these devastating diseases, where Annovis offers its approach.
Overall market sales
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of neurodegenerative diseases. Its operations require significant investment. The growth in total economic revenue, reflected in this chart, creates a favorable investment climate, facilitating the raising of capital for costly clinical trials.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Annovis Bio Inc.
Annovis Bio, Inc. is a biopharmaceutical company developing a drug to treat neurodegenerative diseases such as Alzheimer's and Parkinson's by improving brain signaling. This chart reflects analyst expectations for the clinical trial results of this potentially breakthrough drug.
%20sales%20of%20the%20company%20Annovis%20Bio%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Annovis-Bio-Inc.&v=1772513826152 "Schedule of future (projected) sales of the company Annovis Bio Inc.")
Future (projected) sales of companies in the market segment - Neuro
Annovis Bio is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's by improving axonal transport. This chart shows forecasts for the neuroscience sector, reflecting the enormous need for new approaches to treating these devastating diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772513826257 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Annovis Bio, which develops drugs for neurodegenerative diseases, sees this chart as an indicator of the biotech investment climate. The strong economic forecasts reflected here facilitate the influx of capital needed to fund long-term and expensive clinical trials for Alzheimer's and Parkinson's diseases.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513826288 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Annovis Bio Inc.
Annovis Bio is a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart illustrates the cost of research, showing the amount of investment the company invests in clinical trials.
Market segment marginality - Neuro
Annovis Bio is a biotechnology company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's by targeting multiple neurotoxic proteins simultaneously. The effectiveness of their approach lies in its potential broader therapeutic effect.
Market marginality as a whole
Annovis Bio is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart shows average profitability, and Annovis Bio targets some of the most complex diseases. Their success depends entirely on the results of clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Annovis Bio Inc.
Annovis Bio is a clinical-stage biotechnology company targeting neurodegenerative diseases such as Alzheimer's and Parkinson's. This graph shows its team of scientists. The size of its staff is an indicator of the intensity of its clinical research, which has the potential to change the lives of millions of people.
Share of the company's employees Annovis Bio Inc. within the market segment - Neuro
Annovis Bio develops drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's, targeting the common mechanisms underlying their development. This chart shows the percentage of all neuroscientists Annovis attracts in its field. This is a measure of its scientific potential and the ambitiousness of its approach.
Number of employees in the market segment - Neuro
Annovis Bio is a clinical-stage biopharmaceutical company developing drugs for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. Its team is small and consists of experienced drug developers. This graph illustrates its focused approach. The team's growth will reflect progress in clinical trials.
Number of employees in the market as a whole
Annovis Bio is a biopharmaceutical company developing treatments for neurodegenerative diseases such as Alzheimer's. Its future depends on the results of clinical trials. This chart shows overall activity, but for Annovis Bio, one successful report could change everything, attracting billions in investment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Annovis Bio Inc. (ANVS)
Annovis Bio is an R&D company focused on neurodegenerative diseases. Its market capitalization reflects investors' hopes for the success of its developments. The very high value on this chart is typical for biotech, where a small team of scientists can create a product worth billions of dollars.
%20of%20the%20company%20Annovis%20Bio%20Inc.%20(ANVS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Annovis-Bio-Inc.-ANVS&v=1772513826732 "Chart of market capitalization per employee (in thousands of dollars) of the company Annovis Bio Inc. (ANVS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Annovis Bio, Inc. is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. Its market valuation reflects its enormous potential for success. This metric demonstrates the high value investors place on each scientist working in this highly complex field.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772513826789 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Annovis Bio is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. The chart shows a high valuation per employee, reflecting investor hopes for a breakthrough in the treatment of these complex and widespread diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513826858 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Annovis Bio Inc. (ANVS)
Annovis Bio is a biopharmaceutical company developing drugs to treat neurodegenerative diseases (Alzheimer's, Parkinson's). It's an R&D company. This chart shows the R&D capital burn per scientist. This represents an investment in scientific developments that could generate significant profits in the future.
%20Chart%20Annovis%20Bio%20Inc.%20(ANVS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Annovis-Bio-Inc.-ANVS&v=1772513826862 "Company Profit Per Employee (in thousands of dollars) Chart Annovis Bio Inc. (ANVS)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Annovis Bio (ANVS) is a clinical-stage biopharmaceutical company developing drugs for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart reflects R&D efficiency, demonstrating how efficiently the research team utilizes capital to advance its candidates through costly clinical trials.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772513826916 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Annovis Bio is a clinical-stage biotech company developing drugs to treat neurodegenerative diseases (Alzheimer's, Parkinson's). This is R&D. This graph will show significant losses per employee. This reflects the high cost of scientific research in one of the most complex areas of medicine, where the staff consists of highly paid specialists.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513826943 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Annovis Bio Inc. (ANVS)
Annovis Bio is a biopharmaceutical company treating neurodegenerative diseases such as Alzheimer's and Parkinson's. At the clinical trial stage, this graph doesn't represent sales, but rather hope. Zero revenue per employee is the norm, and success will be measured by trial results, not revenue.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Annovis-Bio-Inc.-ANVS&v=1772513826972 "Sales chart per company employee Annovis Bio Inc. (ANVS)")
Sales per employee in the market segment - Neuro
Annovis Bio is a biotech company developing drugs targeting inflammation to treat neurodegenerative diseases (Alzheimer's, Parkinson's). This chart shows the average revenue per employee in the sector. It serves as a benchmark, demonstrating the level of productivity required for commercial success in this complex field of neuroscience.
Sales per employee for the market as a whole
Annovis Bio, Inc. (ANVS) is a clinical-stage biotechnology company developing drugs for the treatment of neurodegenerative diseases (Alzheimer's and Parkinson's). It is an R&D company. This graph shows the current (zero) commercial return per scientist pending results.
Short shares by company, segment and market as a whole
Shares shorted by company Annovis Bio Inc. (ANVS)
Annovis Bio is a biopharmaceutical company developing a drug for the treatment of neurodegenerative diseases (Alzheimer's, Parkinson's). Its shares have been extremely volatile. The chart shows the number of investors betting that early positive data for its drug will not be confirmed in larger, more rigorous trials, a classic scenario for this sector.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Annovis-Bio-Inc.-ANVS&v=1772513827076 "Short Shares Chart for the Company Annovis Bio Inc. (ANVS)")
Shares shorted by market segment - Neuro
Annovis Bio is a biotech company attacking neurodegenerative diseases (Alzheimer's, Parkinson's) with a single drug. This chart demonstrates the skepticism surrounding this entire niche. Its growth suggests that investors are massively betting against the entire neuroscience development industry, known as the "graveyard" of clinical trials.
Shares shorted by the overall market
Annovis Bio (ANVS) is a clinical-stage biotech working on Alzheimer's. Its value represents hope. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, as they need to refinance R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Annovis Bio Inc. (ANVS)
Annovis Bio is a biotech company working on drugs for neurodegenerative diseases like Alzheimer's and Parkinson's. This is the holy grail of pharma, and the stock is extremely volatile. This oscillator shows when the hype around trial data (above 70) or disappointment with the results (below 30) reach an emotional peak.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Annovis-Bio-Inc.-ANVS&v=1772513827132 "RSI 14 indicator chart for the company's stock Annovis Bio Inc. (ANVS)")
RSI 14 Market Segment - Neuro
Annovis Bio is a biotech company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart measures the collective excitement in the neuroscience biotech sector. It helps determine whether the entire speculative segment is overheated by expectations of a breakthrough.
RSI 14 for the overall market
For Annovis Bio, a biotech company in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ANVS (Annovis Bio Inc.)
Annovis Bio is a biotech company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart shows the average 12-month forecast of analysts, representing their collective speculative bet on the success of clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ANVS-Annovis-Bio-Inc.&v=1772513827169 "A chart showing analyst consensus forecasts for the expected stock price. ANVS (Annovis Bio Inc.)")
The difference between the consensus estimate and the actual stock price ANVS (Annovis Bio Inc.)
Annovis Bio is a biotech company developing a drug (buntanetap) for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their belief in this highly risky R&D bet.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ANVS-Annovis-Bio-Inc.&v=1772513827196 "A chart showing the difference between the consensus forecast and the actual stock price. ANVS (Annovis Bio Inc.)")
Analyst consensus forecast for stock prices by market segment - Neuro
Annovis Bio is another Alzheimer's and Parkinson's disease "hunter." The company is developing a drug that aims to protect nerve cells from death. This chart shows analysts' overall expectations for the entire neuroscience sector. It reflects whether experts believe a breakthrough in dementia treatment is possible or whether they view the sector as an R&D "graveyard."
Analysts' consensus forecast for the overall market share price
Annovis Bio is a biotech company developing drugs to treat neurodegenerative diseases (Alzheimer's, Parkinson's) by restoring the "transport" inside nerve cells. This chart shows the overall risk appetite. For Annovis, working in the most complex field of medicine, overall market optimism is critical to funding long-term and expensive trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Annovis Bio Inc.
Annovis Bio (ANVS) is a clinical-stage biotech focused on neurodegeneration. They are developing a single drug (Buntanetap) that they claim can treat both Alzheimer's and Parkinson's by targeting a common inflammatory mechanism. This chart is a clear indicator of faith in their (very bold) science. Its movement is entirely dependent on their (very risky) clinical trial data.
AKIMA Market Segment Index - Neuro
Annovis Bio (ANVS) is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's by inhibiting the formation of neurotoxic proteins. The chart shows the average index for the segment, helping investors assess how the risks and potential of this approach compare to the average in the neuroscience sector.
The AKIM Index for the overall market
Annovis Bio is a biotech company developing drugs to treat neurodegenerative diseases (Alzheimer's, Parkinson's) by improving axonal transport. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story compares to overall economic trends.
